Exelixis | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Bayer EUR 28.95B 3.9B 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Cytokinetics USD 179.67M 69.86M 2024-12
Eisai JPY 381.62B 54.78B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Exelixis USD 403.77M 9.42M 2025-01
Genmab DKK 5.31B 723M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
MacroGenics USD 55.53M 3.78M 2024-12
Merck USD 28.42B 1.17B 2024-12
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
Sanofi 29.16B 865M 2024-12
Takeda JPY 2.1T 289.27B 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Xencor USD 87.43M 4.54M 2024-12



Exelixis Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.